Abstract: Objective：To explore the treatment efficacy of cabergoline in women with hyperprolactinemia infertility. Methods：109 cases of hyperprolactinemia infertility in our department of obstetrics and gynecology from June 2013 to June 2017 were analyzed retrospectively. The observation group (n=48) was treated with cabergoline, and the control group (n=61) was treated with bromocriptine. The serum PRL of 1, 3 and 6 months after the treatment in two groups, the treatment effect of infertility, the incidence of adverse reactions and drug resistance were recorded. Results：The serum PRL decline values of the observation group were more than those of the control group at 1 month, 3 months and 6 months after the treatment (P＜0.05). The cases of successful pregnancy in the observation group were more than those in the control group, and the difference was statistically significant ( χ2=5.068, P=0.024). The incidence of nausea & vomiting and hypotension in the observation group were lower than those in the control group, the difference was statistically significant (P＜0.05). The drug resistance rate of the observation group was lower than that of the control group (P＞0.05). Conclusions：In the treatment of hyperprolactinemia infertility, the treatment effect of cabergoline is better than that of the bromocriptine in reducing prolactin and the improvement of pregnancy rate, while the incidence of severe adverse reactions is lower.

Key words: Hyperprolactinemia, Infertility, female, Bromocriptine, Cabergoline